Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2015 | Original Article – Clinical Oncology

Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorer prognosis in patients with gastric cancer

Authors: Song Yang, Mingdian Lu, Yuanyuan Chen, Delong Meng, Ruochuan Sun, Dapeng Yun, Zhijie Zhao, Daru Lu, Yongxiang Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2015

Abstract

Purpose

Eukaryotic elongation factor 1 alpha-2 (eEF1A2) is a protein translation factor involved in protein synthesis. It is overexpressed in various cancers, which indicates potential vital functions in tumorigenesis and progression. Our study aims to investigate the expression levels of eEF1A2 in gastric cancer and its roles in clinical practice.

Methods

A total of 129 patients with pathologically confirmed gastric cancer and 24 normal controls were recruited for this study. The expression levels of eEF1A2 in gastric cancer and normal tissues were evaluated by tissue microarrays, quantitative real-time PCR, and western blot analysis. Kaplan–Meier analysis and Cox’s proportional hazards model were used in survival analysis.

Results

Compared with corresponding controls, gastric cancer specimens had significantly increased expressions of eEF1A2 at mRNA and protein levels (both P < 0.05). Moreover, multivariate analysis confirmed that overexpression of eEF1A2 was a significant and independent indicator for predicting poor prognosis of gastric cancer.

Conclusions

Our results showed for the first time that overexpression of eEF1A2 was correlated with worse outcomes in gastric cancer patients, suggesting its critical roles in the carcinogenesis of gastric cancer.

Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, Lee JM (2007) eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 26:3027–3040. doi:10.1038/sj.onc.1210101 CrossRefPubMed

Anand N et al (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31:301–305. doi:10.1038/ng904 PubMed

Chen L, Madura K (2005) Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 65:5599–5606. doi:10.1158/0008-5472.CAN-05-0201 CrossRefPubMed

Chuang SM, Chen L, Lambertson D, Anand M, Kinzy TG, Madura K (2005) Proteasome-mediated degradation of cotranslationally damaged proteins involves translation elongation factor 1A. Mol Cell Biol 25:403–413. doi:10.1128/MCB.25.1.403-413.2005 CrossRefPubMedCentralPubMed

Chung CM et al (2005) Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 43:165–174. doi:10.1002/mc.20098 CrossRefPubMed

Condeelis J (1995) Elongation factor 1 alpha, translation and the cytoskeleton. Trends Biochem Sci 20:169–170CrossRefPubMed

Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, Han J (2009) Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer 124:1614–1621. doi:10.1002/ijc.24163 CrossRefPubMed

Dreher TW, Uhlenbeck OC, Browning KS (1999) Quantitative assessment of EF-1alpha.GTP binding to aminoacyl-tRNAs, aminoacyl-viral RNA, and tRNA shows close correspondence to the RNA binding properties of EF-Tu. J Biol Chem 274:666–672CrossRefPubMed

Duanmin H, Chao X, Qi Z (2013) eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma. Hepatogastroenterology 60:870–875. doi:10.5754/hge12869 PubMed

Grassi G et al (2007) The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie 89:1544–1552. doi:10.1016/j.biochi.2007.07.007 CrossRefPubMed

Gross SR, Kinzy TG (2005) Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12:772–778. doi:10.1038/nsmb979 CrossRefPubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107 CrossRefPubMed

Jimenez C et al (2000) Role of the PI3 K regulatory subunit in the control of actin organization and cell migration. J Cell Biol 151:249–262CrossRefPubMedCentralPubMed

Kim J et al (2009) The role of translation elongation factor eEF1A in intracellular alkalinization-induced tumor cell growth Laboratory investigation. J Tech Methods Pathol 89:867–874. doi:10.1038/labinvest.2009.53 CrossRef

Knudsen SM, Frydenberg J, Clark BF, Leffers H (1993) Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. European J Biochem/FEBS 215:549–554CrossRef

Kulkarni G et al (2007) Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat 102:31–41. doi:10.1007/s10549-006-9315-8 CrossRefPubMed

Lamberti A et al (2007) C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 14:952–962. doi:10.1038/sj.cdd.4402102 PubMed

Lee MH, Surh YJ (2009) eEF1A2 as a putative oncogene. Ann N Y Acad Sci 1171:87–93. doi:10.1111/j.1749-6632.2009.04909.x CrossRefPubMed

Li R et al (2006) Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 25:2628–2635. doi:10.1038/sj.onc.1209289 CrossRefPubMed

Lund A, Knudsen SM, Vissing H, Clark B, Tommerup N (1996) Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics 36:359–361. doi:10.1006/geno.1996.0475 CrossRefPubMed

McClatchy DB, Fang G, Levey AI (2006) Elongation factor 1A family regulates the recycling of the M4 muscarinic acetylcholine receptor. Neurochem Res 31:975–988. doi:10.1007/s11064-006-9103-1 CrossRefPubMed

Munshi R, Kandl KA, Carr-Schmid A, Whitacre JL, Adams AE, Kinzy TG (2001) Overexpression of translation elongation factor 1A affects the organization and function of the actin cytoskeleton in yeast. Genetics 157:1425–1436PubMedCentralPubMed

Murakami D, Tsujitani S, Osaki T, Saito H, Katano K, Tatebe S, Ikeguchi M (2007) Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer 10:45–51. doi:10.1007/s10120-006-0410-7 CrossRefPubMed

Newbery HJ et al (2005) Progressive loss of motor neuron function in wasted mice: effects of a spontaneous null mutation in the gene for the eEF1 A2 translation factor. J Neuropathol Exp Neurol 64:295–303PubMed

Ohuchida K et al (2005) The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Cancer Res 11:7785–7793. doi:10.1158/1078-0432.CCR-05-0714

Olson JM, Hallahan AR (2004) p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10:125–129. doi:10.1016/j.molmed.2004.01.007 CrossRefPubMed

Panasyuk G, Nemazanyy I, Filonenko V, Negrutskii B, El’skaya AV (2008) A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules. Int J Biochem Cell Biol 40:63–71. doi:10.1016/j.biocel.2007.08.014 CrossRefPubMedCentralPubMed

Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM (2008) The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol 108:561–568. doi:10.1016/j.ygyno.2007.11.019 CrossRefPubMed

Potrc S, Gadiijev E, Hajdinjak T, Kavalar R (2007) Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Hepatogastroenterology 54:308–314PubMed

Sanges C et al (2012) Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis 3:276. doi:10.1038/cddis.2012.16 CrossRef

Shamovsky I, Ivannikov M, Kandel ES, Gershon D, Nudler E (2006) RNA-mediated response to heat shock in mammalian cells. Nature 440:556–560. doi:10.1038/nature04518 CrossRefPubMed

Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S (2000) Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 89:255–261CrossRefPubMed

Soares DC, Barlow PN, Newbery HJ, Porteous DJ, Abbott CM (2009) Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS ONE 4:e6315. doi:10.1371/journal.pone.0006315 CrossRefPubMedCentralPubMed

Suda M et al (1999) Overproduction of elongation factor 1alpha, an essential translational component, causes aberrant cell morphology by affecting the control of growth polarity in fission yeast. Genes Cells 4:517–527CrossRefPubMed

Sun B, Chu D, Li W, Chu X, Li Y, Wei D, Li H (2009) Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neuro Oncol 94:213–219. doi:10.1007/s11060-009-9859-7 CrossRef

Thornton S, Anand N, Purcell D, Lee J (2003) Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 81:536–548. doi:10.1007/s00109-003-0461-8 CrossRefPubMed

Tomlinson VA et al (2005) Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 5:113. doi:10.1186/1471-2407-5-113 CrossRefPubMedCentralPubMed

Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM (2011) Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 17:5463–5472. doi:10.1158/1078-0432.CCR-10-3096 CrossRefPubMed

Xu C, Hu DM, Zhu Q (2013) eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. Clin Exp Metastasis 30:933–944. doi:10.1007/s10585-013-9593-6 CrossRefPubMed

Yokota T et al (2002) Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res 22:3673–3677PubMed

Yokota T et al (2004) Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 39:380–384CrossRefPubMed

Zhang S et al (2010) A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis 31:1251–1258. doi:10.1093/carcin/bgq089 CrossRefPubMed

Zheng L, Wang L, Ajani J, Xie K (2004) Molecular basis of gastric cancer development and progression. Gastric Cancer 7:61–77. doi:10.1007/s10120-004-0277-4 CrossRefPubMed

Title: Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorer prognosis in patients with gastric cancer
Authors: Song Yang
Mingdian Lu
Yuanyuan Chen
Delong Meng
Ruochuan Sun
Dapeng Yun
Zhijie Zhao
Daru Lu
Yongxiang Li
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1897-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function

The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)

Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy

Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy

Stomach cancer mortality among workers exposed to asbestos: a meta-analysis

Systematic evaluation of cancer risk associated with DNMT3B polymorphisms

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage